NCT07059767View on ClinicalTrials.gov

Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Asthma (Diagnosis)
Interventions
DRUG

ETH47

single intranasal dose of ETH47

DRUG

Placebo

single intranasal dose of placebo

Trial Locations (1)

Unknown

RECRUITING

Virtus Respiratory Research Ltd and Imperial College Healthcare NHS Trust, London

Sponsors

Lead Sponsor

Ethris GmbH
All Listed Sponsors
collaborator

VirTus Respiratory Research Ltd

UNKNOWN

lead

Ethris GmbH

INDUSTRY

NCT07059767 - Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge | Biotech Hunter | Biotech Hunter